Market Dynamics
The global demand for antibody drug conjugates is being driven by advances in medical technology. Furthermore, increasing cancer cases, a rise in the obese population, and an aging population are some of the market's main driving factors. Furthermore, preclinical research, increased research activities on antibody therapies, increased research on advanced drug discoveries, increased research on oncology diseases, and growing collaboration between research institutes, biopharmaceuticals, and biotechnology companies are fueling the market and are expected to drive the market of antibody drug conjugates in the near future. Increased cancer incidence worldwide, unhealthy urban lifestyles, and increased tobacco and alcohol use across geographies are all significant cancer risk factors.
Market Overview
The global antibody drug conjugate market is touted to rise at a CAGR of about 19% during the forecast period of 2017–2023.
Market segmentation
The global antibody drug conjugate market is segmented on the basis of type, product, technology, application, and end-user.
On the basis of type, the global antibody drug conjugate market is segmented into monoclonal antibodies, linker, drug/toxin, and others.
On the basis of product, the global antibody drug conjugate market is segmented into Adcertis, Kadcyla, and others.
On the basis of technology, the global antibody drug conjugate market is classified into ImmunoGen technology, Seattle Genetics technology, Immunomedics technology, and others.
On the basis of end-user, the global antibody drug conjugate market is classified into hospitals, specialized cancer centers, academic research institutes, biotechnology companies, biopharmaceutical companies, and others.
Competitive Dashboard
Some major players in the global antibody drug conjugate market include Seattle Genetics (US), ImmunoGen, Inc. (US), Roche Holding AG (Switzerland), Genentech (US), Concortis Biotherapeutics (US), Agensys, Inc. (US), Antikor (UK), Immunomedics (US), Pfizer Inc. (US), Celldex Therapeutics (US), Millennium Pharmaceuticals (US), AbbVie Inc. (US), Bayer HealthCare (Germany), Astellas Pharma/Agensys (Japan), Progenics Pharmaceuticals (US), Mersana Therapeutics (US), Synthon (US), Heidelberg Pharma (Germany), Oxford BioTherapeutics (US), and others.
